Evaluation of efficacy and safety of FOLFIRI for elderly patients with gastric cancer: A first-line phase II study - 10/12/11
, Réné Brunet a, Yves Becouarn a, Jean-Louis Legoux b, Jérôme Dauba c, Laurent Cany d, Denis Smith e, Dominique Auby c, Éric Terrebonne b, Laurent Traissac f, Cécile Mertens a, Pierre Soubeyran a, j, Carine Bellera g, i, Muriel Rainfray h, j, Simone Mathoulin-Pélissier g, i, j
Corresponding author. Tel.: +33 05 56 33 32 42; fax: +33 05 56 33 33 83.Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 8 |
| Iconographies | 2 |
| Vidéos | 0 |
| Autres | 0 |
Summary |
Objective |
Current chemotherapy protocols for gastric cancer present high toxicity. The FOLFIRI regimen has shown promising results with elderly colorectal cancer patients and for gastric cancer patients but this is the first report on elderly gastric cancer patients.
Design |
In this multicenter non-randomized phase II trial, we administered the FOLFIRI chemotherapy protocol (irinotecan [180mg/m2], fluorouracil [5-FU] [400mg/m2] and folinic acid 400mg/m2 or 200mg/m2 of l-folinic acid) to patients aged over 70years with locally-advanced or metastatic gastric cancer combined with Comprehensive Geriatric Assessment (CGA). Responses were assessed at 2months.
Results |
Forty-two patients received eight cycles of the FOLFIRI regimen, with 82.5% of patients showing disease control: 10 patients (26%) showing objective (partial or complete) responses and 23 (57.5%) showing stable disease. One-year overall survival (OS) was 41.5% [95%CI 26.5–56.0] and one-year progression-free survival (PFS) was 31.8% [95%CI 18.4–46.1%]. We observed 10 Grade 3/4 hematologic toxicities with one febrile neutropenia. CGA data demonstrated that geriatric functions were not altered by treatment and that nutritional status improved over treatment.
Conclusions |
Results show excellent disease control and relatively high survival rates with limited toxicity similar to younger patients indicating that this regimen should be considered as a possible treatment in advanced gastric cancer of the elderly.
Le texte complet de cet article est disponible en PDF.Plan
 | Presented in part at the 46th Annual meeting of the American Society of Clinical Oncology, Chicago, IL, June 4–8, 2010. |
Vol 35 - N° 12
P. 823-830 - décembre 2011 Retour au numéro
Article précédent
- Small bowel ischemia after angiographic embolization for angiodysplasia of lower gastrointestinal tract: The case for conservative management
- S.W. Suh, Y.S. Choi, H. Kim, B.G. Kim
- History of cancer in first degree relatives of Barrett’s esophagus patients: A case-control study
- Antonella De Ceglie, Rosa Filiberti, Sabrina Blanchi, Vincenzo Fontana, Deborah A. Fisher, Enzo Grossi, Teresa Lacchin, Marina De Matthaeis, Orazio Ignomirelli, Roberta Cappiello, Domenico Della Casa, Monica Foti, Francesco Laterza, Riccardo Rosati, Vito Annese, Gaetano Iaquinto, Massimo Conio
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?